Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multi-center, Phase 1/2 study to determine the MTD and assess the
safety, tolerability, PK, immunogenicity, and anti-leukemia activity of IMGN632 when
administered as monotherapy to patients with CD123+ disease.
The study is enrolling a pivotal cohort of frontline BPDCN patients and a cohort of
relapsed/refractory BPDCN patients.